Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria

Clinical & Experimental Allergy 2026 Open access

Read full text
Authors: Francisco Martins, Ilaria Trave, Ana Sofia Pereira, Margarida Gonçalo
DOI: 10.1111/cea.70236
Cited by: 0
References: 8

Abstract

Summary Obese patients with chronic spontaneous urticaria often require progressively increasing omalizumab doses to maintain previous disease control. Acquired resistance to omalizumab may be explained by immunological and pharmacokinetic changes in the setting of obesity.

Fields of Study & Subjects

Urticaria and Related Conditions Mast cells and histamine Dermatology and Skin Diseases

Publication details

Journal / source
Clinical & Experimental Allergy
Volume
56
Issue
6
Pages
671–673
Publication date
8 February 2026
Language
EN